Final order imposing conditions on AbbVie’s acquisition of Allergan approved by US FTC
MLex Summary: The US Federal Trade Commission approved a final order settling charges that AbbVie’s $63 billion acquisition of Allergan would violate federal antitrust law. Under the order, AbbVie and Allergan...To view the full article, register now.
Already a subscriber? Click here to view full article